Betty W Chang

US Patent:

20130178483, Jul 11, 2013

Filed:

Jun 28, 2012

Appl. No.:

13/536799

Inventors:

Joseph J. Buggy - Mountain View CA, US
Betty Y. Chang - Cupertino CA, US

Assignee:

Pharmacyclics, Inc. - Sunnyvale CA

International Classification:

C07D 487/04

US Classification:

5142621

Abstract:

Disclosed herein are methods and compounds for inhibiting bone and/or cartilage resorption in an individual. The methods comprise administering to the individual a composition comprising a therapeutically effective amount of a compound that is an irreversible inhibitor of a Bruton's tyrosine kinase (BTK), or a pharmaceutically acceptable salt thereof. Also described are irreversible inhibitors of Btk and methods for the preparation of the compounds. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the inhibition of cancer metastasis, and for inhibition of bone or cartilage resorption in cancer patients.

US Patent:

20040071659, Apr 15, 2004

Filed:

Apr 29, 2002

Appl. No.:

10/135872

Inventors:

Betty Chang - Cupertino CA, US
Wei Wei Wu - Redwood City CA, US
James McArthur - San Carlos CA, US
Salil Patel - South Plainfield NJ, US
Karin Jooss - San Francisco CA, US
Michael Mendez - Albuquerque NM, US
Brian Donahue - Los Altos CA, US

International Classification:

A61K048/00
C12N007/00
C12N015/861

US Classification:

424/093200, 435/456000, 435/235100

Abstract:

The present invention provides anti-angiogenic compositions and methods, based on gene delivery vectors that include the coding sequence for an anti-angiogenic compound.

US Patent:

20200397895, Dec 24, 2020

Filed:

Jan 24, 2020

Appl. No.:

16/752231

Inventors:

- Sunnyvale CA, US
Betty Chang - Cupertino CA, US
Patrick Ng - Sunnyvale CA, US
Holbrook Kohrt - San Francisco CA, US

International Classification:

A61K 39/395
C07K 16/28
A61K 31/519
A61K 45/06

Abstract:

Combinations of Bruton's tyrosine kinase (Btk) inhibitors, e.g., 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, with immunotherapy are provided. Also provided are methods of treating cancers, and autoimmune disorders by administering combinations of Bruton's tyrosine kinase (Btk) inhibitors, e.g., 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, and an immune checkpoint inhibitor.

US Patent:

20200030330, Jan 30, 2020

Filed:

Feb 28, 2019

Appl. No.:

16/289511

Inventors:

- Sunnyvale CA, US
Betty Y. Chang - Cupertino CA, US
Taisei Kinoshita - San Jose CA, US
Ssucheng J. Hsu - Pinole CA, US
Jun Chen - San Jose CA, US
Yujun Huang - San Diego CA, US

International Classification:

A61K 31/519
A61K 45/06
A61P 35/00
A61K 31/436
A61K 31/506
A61K 31/337
C07K 16/28
A61K 39/395

Abstract:

Disclosed arc compositions, methods, and kits for treating a solid tumor comprising co- administering to an individual in need thereof a BTK inhibitor and an mTOR inhibitor: a taxane, or an EGFR inhibitor.

US Patent:

20180071293, Mar 15, 2018

Filed:

Jul 14, 2017

Appl. No.:

15/650830

Inventors:

- Sunnyvale CA, US
Tarak D. Mody - Sunnyvale CA, US
Richard B. Love - Montara CA, US
John C. Byrd - Columbus OH, US
Betty Y. Chang - Cupertino CA, US
Jason A. Dubovsky - Columbus OH, US
Natarajan Muthusamy - Columbus OH, US
Amy J. Johnson - Columbus OH, US

International Classification:

A61K 31/519
A61K 45/06

Abstract:

Described herein are methods and compositions comprising a covalent TEC family kinase inhibitor for use in adjuvant therapy, including adjuvant cancer therapy, vaccination and treatment of immune disorders and pathogenic infections.

US Patent:

20180071295, Mar 15, 2018

Filed:

Jul 21, 2017

Appl. No.:

15/656394

Inventors:

- Sunnyvale CA, US
- Beerse, BE
Betty Y. Chang - Cupertino CA, US
Ling Xue - Beijing, CN
Sriram Balasubramanian - North Wales PA, US
Leo Cheung - Fremont CA, US

International Classification:

A61K 31/519
A61K 45/06
A61K 38/21
A61K 38/20
A61K 38/19
A61K 38/00
A61K 31/454
A61K 31/426
A61K 31/4196
A61K 31/4164
A61K 38/31

Abstract:

Disclosed herein are methods, compositions, and kits for treating a B-cell malignancy comprising administering a combination of a BTK inhibitor (e.g. ibrutinib) and a PIM inhibitor. Also disclosed herein are methods, compositions, and kits for treating a BTK-resistant B-cell malignancy comprising administering a combination of a BTK inhibitor (e.g. ibrutinib) and a PIM inhibitor.

US Patent:

20170354655, Dec 14, 2017

Filed:

Nov 17, 2015

Appl. No.:

15/527443

Inventors:

- Sunnyvale CA, US
Betty Y. Chang - Cupertino CA, US
Hsu-Ping Kuo - Sunnyvale CA, US

International Classification:

A61K 31/517
A61K 31/519
A61K 45/06

Abstract:

Provided are compositions for and methods of treating a B-cell malignancy in a subject in need thereof, by administering to the subject a therapeutically effective amount of a combination comprising an inhibitor of a BTK inhibitor and a TLR inhibitor.

US Patent:

20170027941, Feb 2, 2017

Filed:

Jul 29, 2016

Appl. No.:

15/223646

Inventors:

- Sunnyvale CA, US
Betty Y. Chang - Cupertino CA, US
Taisei Kinoshita - San Jose CA, US
Ssucheng J. Hsu - Pinole CA, US
Jun Chen - San Jose CA, US
Yujun Huang - Campbell CA, US

International Classification:

A61K 31/519
A61K 39/395
A61K 31/337
C07K 16/28
A61K 31/436
A61K 31/506

Abstract:

Disclosed are compositions, methods, and kits for treating a solid tumor comprising co-administering to an individual in need thereof a BTK inhibitor and an mTOR inhibitor; a taxane, or an EGFR inhibitor.